Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
BOULDER, Colo. and HUNTINGTON BEACH, Calif., Dec. 11, 2013 /PRNewswire/ -- BiOptix continues support of the global antibody engineering and therapeutics research community through participation in IBC's 24th Annual Antibody Engineering & Therapeutics Conference and annual meeting of The Antibody Society, being held in Huntington Beach, CA from December 8 – 12, 2013. During the event, BiOptix will be highlighting the BiOptix Innovators Program, a unique and innovative product evaluation platform that allows customers to try BiOptix SPR technology independently in their lab, on their timeframe and with complete customer and technical support during the process.
While presenting new antibody kinetics data from BiOptix, Ken Wilczek, Vice President, Sales & Marketing for BiOptix noted: "Antibody research and therapeutics continues to be a vital and growing market worldwide-and is a perfect match for the BiOptix 404pi." "With a unique platform, multiple sensor chemistries and an industry -leading instrumentation demo initiative known as the BiOptix Innovators Program, BiOptix is becoming a principal choice for antibody researchers who require robust and repeatable kinetics." Additional details about the BiOptix Innovators Program, in which BiOptix seeks to partner with academic, pharmaceutical and biotechnology/drug discovery research labs can be found at: http://www.bioptix.com/products/innovators-program
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction-with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
©2012 PR Newswire. All Rights Reserved.